Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 2Genitourinary 1CNS 1

Conditions

Pheochromocytoma 2Paraganglioma 1

Interventions

lutetium Lu 177 dotatate 36Everolimus 32pembrolizumab 24Temozolomide 21Magnetic Resonance Spectroscopy 21Nivolumab 18lenvatinib 17gallium Ga 68 dotatate 16cabozantinib 15Cisplatin 15lanreotide 143-Iodobenzylguanidine 14Capecitabine 13trametinib 12dabrafenib 12Bevacizumab 12Octreotide 11Surveys and Questionnaires 10Surgical Procedures, Operative 10Sunitinib 10Radiosurgery 10Positron Emission Tomography Computed Tomography 10Blood Specimen Collection 10Sorafenib 9Paclitaxel 9Ipilimumab 9Carboplatin 9surufatinib 8Etoposide 8Doxorubicin 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Doxazosin × Endocrine × Clear all
NCT01379898 2024-09-19

PRESCRIPT

University Medical Center Groningen

Phase 4 Completed
134 enrolled
Endocrine

Pheochromocytoma

NCT03176693 2023-11-20

Preoperative Alpha Blockade for Pheochromocytoma

University of California, Los Angeles

Phase 3 Completed
39 enrolled 8 charts
CNSEndocrine

Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡